In the TCGA‐BLCA cohort, patients with high IGF2BP2 expression exhibited significantly poorer overall survival (p = 0.014, Figure 4E) and higher expression in high‐grade tumors (p = 3.9e‐06, Figure 4F), linking it to tumor aggressiveness. Here, IGF2BP2 is linked to bladder transitional cell carcinoma.